Skip to main content

Table 1 Multivariate Cox regression analysis of tumor-infiltrating lymphocytes and immune markers for relapse-free survival and overall survival in triple-negative breast cancer

From: An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

  Relapse-free survival Overall survival
Variable HR 95% CI P value HR 95% CI P value
LPBC 0.24 0.06–1.00 5.10E-02 0.32 0.10–1.03 5.60E-02
 Age 1.09 0.66–1.80 7.28E-01 1.13 0.68–1.87 6.27E-01
 Histologic grade 1.66 0.78–3.53 1.91E-01 1.85 0.87–3.94 1.09E-01
 Nodal status 3.44 1.72–6.88 5.00E-04 3.19 1.59–6.39 1.00E-03
 Tumor size 1.21 0.74–1.99 4.48E-01 1.27 0.77–2.09 3.48E-01
 Tumor stage 1.34 0.76–2.35 3.12E-01 1.38 0.78–2.43 2.69E-01
TILsa 0.93 0.89–0.96 1.00E-04 0.93 0.90–0.95 1.00E-04
 Age 0.97 0.58–1.61 8.97E-01 1.02 0.61–1.71 9.32E-01
 Histologic grade 1.34 0.63–2.87 4.48E-01 1.76 0.83–3.75 1.40E-01
 Nodal status 2.91 1.43–5.90 3.10E-03 2.59 1.27–5.28 8.70E-03
 Tumor size 1.11 0.68–1.83 6.70E-01 1.15 0.70–1.90 5.73E-01
 Tumor stage 1.46 0.82–2.62 2.00E-01 1.45 0.80–2.63 2.19E-01
CD8 0.58 0.34–0.97 3.72E-02 0.58 0.34–0.97 3.88E-02
 Age 1.12 0.68–1.85 6.66E-01 1.16 0.70–1.93 5.58E-01
 Histologic grade 1.71 0.80–3.65 1.67E-01 1.91 0.90–4.08 9.34E-02
 Nodal status 3.46 1.73–6.90 4.00E-04 3.23 1.62–6.45 9.00E-04
 Tumor size 1.20 0.73–1.97 4.80E-01 1.26 0.76–2.07 3.70E-01
 Tumor stage 1.35 0.76–2.37 3.01E-01 1.35 0.76–2.40 2.99E-01
FOXP3 0.52 0.31–0.89 1.71E-02 0.55 0.32–0.94 2.90E-02
 Age 1.10 0.67–1.83 6.98E-01 1.16 0.70–1.92 5.70E-01
 Histologic grade 1.81 0.84–3.87 1.28E-01 2.01 0.94–4.30 7.27E-02
 Nodal status 3.54 1.79–7.00 3.00E-04 3.30 1.67–6.53 6.00E-04
 Tumor size 1.23 0.75–2.03 4.05 E-01 1.30 0.79–2.13 3.06E-01
 Tumor stage 1.37 0.79–2.41 2.65E-01 1.38 0.78–2.42 2.66E-01
  1. Multivariate analysis adjusted for age (≥50 vs <5 years), histologic grade (III vs – I-II), nodal status (1 vs 0), tumor size (>20 mm vs ≤20 mm), and tumor stage (III vs I–II). Significant P values are in italics. aTreated as a continuous variable for each 10% increment. CI confidence interval, HR hazard ratio, LPBC lymphocyte-predominant breast cancer, TILs tumor-infiltrating lymphocytes